Mergers & Acquisitions ·
Repligen Corporation announced that the Hart-Scott-Rodino antitrust waiting period for its proposed acquisition of…
RGENRepligen Corp
Repligen Corporation announced that the Hart-Scott-Rodino antitrust waiting period for its proposed acquisition of BioLife Solutions expired on September 3, 2026. The transaction involves Repligen acquiring all outstanding shares of BioLife common stock for $11.25 cash and 0.1442 shares of Repligen common stock per share. Completion remains subject to customary closing conditions, including adoption by BioLife's stockholders at a special meeting scheduled for October 5, 2026. Repligen Corporation operates in the biotechnology industry, providing equipment, consumables, and services for the development and manufacture of biological drugs.